International external validation of a stratification tool to identify branch-duct intraductal papillary mucinous neoplasms at lowest risk of progression.
intraductal papillary mucinous neoplasm
pancreatic cyst
prediction
prognosis
screening
surveillance
Journal
United European gastroenterology journal
ISSN: 2050-6414
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
11
11
2021
accepted:
20
01
2022
pubmed:
25
2
2022
medline:
4
5
2022
entrez:
24
2
2022
Statut:
ppublish
Résumé
Identifying branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) at lowest risk of progression may allow for a reduced intensity of surveillance. We aimed to externally validate the previously developed Dutch-American Risk stratification Tool (DART-1; https://rtools.mayo.edu/DART/), which identifies cysts at low risk of developing worrisome features (WFs) or high-risk stigmata (HRS). Three prospective cohorts of individuals under surveillance for BD-IPMNs were combined, independent from the original development cohort. We assessed the performance (discrimination and calibration) of DART-1, a multivariable Cox-proportional logistic regression model with five predictors for the development of WFs or HRS. Of 832 individuals (mean age 77 years, SD 11.5) under surveillance for a median of 40 months (IQR 44), 163 (20%) developed WFs or HRS. DART-1's discriminative ability (C-statistic 0.68) was similar to that in the development cohort (0.64-0.72) and showed moderate calibration. DART-1 adequately estimated the risk for patients in the middle risk quintile, and slightly underestimated it in the lowest quintiles. Their range of predicted versus observed 3-year risk was 0%-0% versus 0%-3.7% for Q1; 0.3%-0.4% versus 3%-11% for Q2; and 2.6%-3% versus 2.4%-9.8% for Q3. The development of WFs or HRS was associated with pancreatic cancer (p < 0.001). Vice versa, in absence of WFs or HRS, the risk of malignancy was low (0.3%). The performance of DART-1 to predict the development of WFs or HRS in BD-IPMN was validated in an external international cohort, with a discriminative ability equal as in the development cohort. Risk estimations were most accurate for patients with BD-IPMNs in the middle risk quintile and slightly underestimated in the lowest quintiles.
Sections du résumé
BACKGROUND
Identifying branch-duct intraductal papillary mucinous neoplasms (BD-IPMNs) at lowest risk of progression may allow for a reduced intensity of surveillance.
OBJECTIVE
We aimed to externally validate the previously developed Dutch-American Risk stratification Tool (DART-1; https://rtools.mayo.edu/DART/), which identifies cysts at low risk of developing worrisome features (WFs) or high-risk stigmata (HRS).
METHODS
Three prospective cohorts of individuals under surveillance for BD-IPMNs were combined, independent from the original development cohort. We assessed the performance (discrimination and calibration) of DART-1, a multivariable Cox-proportional logistic regression model with five predictors for the development of WFs or HRS.
RESULTS
Of 832 individuals (mean age 77 years, SD 11.5) under surveillance for a median of 40 months (IQR 44), 163 (20%) developed WFs or HRS. DART-1's discriminative ability (C-statistic 0.68) was similar to that in the development cohort (0.64-0.72) and showed moderate calibration. DART-1 adequately estimated the risk for patients in the middle risk quintile, and slightly underestimated it in the lowest quintiles. Their range of predicted versus observed 3-year risk was 0%-0% versus 0%-3.7% for Q1; 0.3%-0.4% versus 3%-11% for Q2; and 2.6%-3% versus 2.4%-9.8% for Q3. The development of WFs or HRS was associated with pancreatic cancer (p < 0.001). Vice versa, in absence of WFs or HRS, the risk of malignancy was low (0.3%).
CONCLUSIONS
The performance of DART-1 to predict the development of WFs or HRS in BD-IPMN was validated in an external international cohort, with a discriminative ability equal as in the development cohort. Risk estimations were most accurate for patients with BD-IPMNs in the middle risk quintile and slightly underestimated in the lowest quintiles.
Identifiants
pubmed: 35199484
doi: 10.1002/ueg2.12207
pmc: PMC8911544
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
169-178Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Informations de copyright
© 2022 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of United European Gastroenterology.
Références
Pancreatology. 2017 Sep - Oct;17(5):738-753
pubmed: 28735806
Ann Surg. 2017 Sep;266(3):536-544
pubmed: 28657939
Pancreas. 2016 Oct;45(9):1227-32
pubmed: 27171512
Br J Surg. 2015 Feb;102(3):148-58
pubmed: 25627261
Gastroenterology. 2018 Feb;154(3):576-584
pubmed: 29074452
Ann Surg. 2015 May;261(5):984-90
pubmed: 25493361
J Clin Epidemiol. 2006 Oct;59(10):1102-9
pubmed: 16980151
Gastroenterology. 2020 Jan;158(1):226-237.e5
pubmed: 31473224
Gastrointest Endosc. 2016 Sep;84(3):436-45
pubmed: 26905937
Gut. 2017 Oct;66(10):1811-1817
pubmed: 27390303
JAMA Netw Open. 2020 Nov 2;3(11):e2022933
pubmed: 33252689
Ann Surg. 2015 May;261(5):976-83
pubmed: 24979607
Aliment Pharmacol Ther. 2019 Oct;50(7):789-799
pubmed: 31429105
J Gastroenterol Hepatol. 2018 Jan;33(1):320-328
pubmed: 28872701
AJR Am J Roentgenol. 2017 Aug;209(2):320-326
pubmed: 28590817
Gut. 2018 May;67(5):789-804
pubmed: 29574408
Korean J Radiol. 2017 Nov-Dec;18(6):915-925
pubmed: 29089824
Gastroenterology. 2007 Jul;133(1):72-9; quiz 309-10
pubmed: 17631133
Am J Gastroenterol. 2019 Oct;114(10):1678-1684
pubmed: 31449158
Gastroenterology. 2015 Apr;148(4):819-22; quize12-3
pubmed: 25805375
Pancreatology. 2019 Jan;19(1):2-9
pubmed: 30503370
Ann Surg. 2016 Mar;263(3):557-64
pubmed: 25822687
Ann Surg. 2018 Jan;267(1):157-163
pubmed: 28079542
Am J Gastroenterol. 2018 Apr;113(4):464-479
pubmed: 29485131
Ann Surg Oncol. 2017 Apr;24(4):1120-1126
pubmed: 27822633
Clin Gastroenterol Hepatol. 2016 Jun;14(6):865-871
pubmed: 26656298
Am J Gastroenterol. 2017 Jul;112(7):1153-1161
pubmed: 28244498
Gastroenterology. 2017 Nov;153(5):1284-1294.e1
pubmed: 28739282
Pancreas. 2020 Apr;49(4):552-560
pubmed: 32282769
Ann Surg. 2015 Nov;262(5):875-80; discussion 880-1
pubmed: 26583679
Dig Liver Dis. 2016 May;48(5):473-479
pubmed: 26965783
United European Gastroenterol J. 2022 Mar;10(2):169-178
pubmed: 35199484
J Clin Epidemiol. 2007 Sep;60(9):979
pubmed: 17689816
J Gastroenterol Hepatol. 2020 May;35(5):877-884
pubmed: 31758719
Pancreatology. 2012 May-Jun;12(3):183-97
pubmed: 22687371
Eur J Radiol Open. 2020 Aug 21;7:100250
pubmed: 32884981
Gastroenterol Clin North Am. 2007 Dec;36(4):831-49, vi
pubmed: 17996793
Gastrointest Endosc. 2016 Jul;84(1):81-6
pubmed: 26524643